HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. Welcome to HatchMet 2025 full-year result and business update. Today, we're going to go through our result in a formal presentation by our senior management, and then it will be followed by Q&A. Before I start, let's turn to page two with our usual safe harbor statement. Basically, the performance and results of our operation contained within this presentation are historical in nature. and the past performance is no guarantee of future results the information in this presentation is subject to changes and hutchmed has no liability for any loss arising from the use of these contents um my name is david i'm the head of io of hutchmed we are very happy that we're going to have our senior management to present the results Let me hand off the time to our Acting Chief Executive Officer and Chief Financial Officer, Jonny Chan. Jonny. Thank you, David. And thank you everyone for attending Hachimed's 2025 Results webcast. Joining me today is our Deputy CFO, Lorenzo Jill, who will give us an overview of our financial performance. Our Head of Commercial, George Yuan, who will share with you our commercial performance and our head of discovery, Dr. Guangxiu Dai, who will provide an update on our R&D pipeline progress. Next slide, please. A quick highlight of our 2025 achievements. We are pleased with our ExChina Fuseca sales, which had 26% growth versus last year, resulting in $366 million in in-market sales. More importantly, Fuseca has rolled out to over 38 countries already. As for our China sales, it has rebounded in the second half of the year, achieving 21% in-market sales growth versus our first half intron results. In terms of our cash position, we have about $1.4 billion, which allows us to accelerate our global ATTC development and provide resources to...